Zetagen Therapeutics has raised $12 million in Series B1 funding to advance its intratumoral therapies for primary and metastatic breast cancer. Led by CEO Joe C Loy, the NY-based biotech is developing ZetaMet, ZetaMast and ZetaPrime to directly deliver cancer-killing compounds into tumours, reduce toxicity, regenerate bone, and phase into new clinical trials.